vs
通用动力（GD）与礼来（LLY）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是通用动力的1.4倍（$19.3B vs $13.5B），礼来净利率更高（34.4% vs 8.3%，领先26.1%），礼来同比增速更快（42.6% vs 10.3%），过去两年礼来的营收复合增速更高（48.3% vs 6.1%）
通用动力是总部位于美国弗吉尼亚州雷斯顿的工业科技企业，是全球领先的先进军工装备研发生产商，产品覆盖核潜艇、主战坦克、装甲战车等多种品类，同时生产湾流系列公务机，也提供信息技术服务，位列美国前百名国防承包商第三位。
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
GD vs LLY — 直观对比
营收规模更大
LLY
是对方的1.4倍
$13.5B
营收增速更快
LLY
高出32.3%
10.3%
净利率更高
LLY
高出26.1%
8.3%
两年增速更快
LLY
近两年复合增速
6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5B | $19.3B |
| 净利润 | $1.1B | $6.6B |
| 毛利率 | — | 82.5% |
| 营业利润率 | 10.5% | 42.8% |
| 净利率 | 8.3% | 34.4% |
| 营收同比 | 10.3% | 42.6% |
| 净利润同比 | 13.2% | 50.5% |
| 每股收益（稀释后） | $4.10 | $7.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDLLY
| Q1 26 | $13.5B | — | ||
| Q4 25 | $14.4B | $19.3B | ||
| Q3 25 | $12.9B | $17.6B | ||
| Q2 25 | $13.0B | $15.6B | ||
| Q1 25 | $12.2B | $12.7B | ||
| Q4 24 | $13.3B | $13.5B | ||
| Q3 24 | $11.7B | $11.4B | ||
| Q2 24 | $12.0B | $11.3B |
净利润GDLLY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $6.6B | ||
| Q3 25 | $1.1B | $5.6B | ||
| Q2 25 | $1.0B | $5.7B | ||
| Q1 25 | $994.0M | $2.8B | ||
| Q4 24 | $1.1B | $4.4B | ||
| Q3 24 | $930.0M | $970.3M | ||
| Q2 24 | $905.0M | $3.0B |
毛利率GDLLY
| Q1 26 | — | — | ||
| Q4 25 | — | 82.5% | ||
| Q3 25 | — | 82.9% | ||
| Q2 25 | — | 84.3% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | 82.2% | ||
| Q3 24 | — | 81.0% | ||
| Q2 24 | — | 80.8% |
营业利润率GDLLY
| Q1 26 | 10.5% | — | ||
| Q4 25 | 10.1% | 42.8% | ||
| Q3 25 | 10.3% | 41.1% | ||
| Q2 25 | 10.0% | 43.6% | ||
| Q1 25 | 10.4% | 27.2% | ||
| Q4 24 | 10.7% | 37.2% | ||
| Q3 24 | 10.1% | 13.9% | ||
| Q2 24 | 9.7% | 31.1% |
净利率GDLLY
| Q1 26 | 8.3% | — | ||
| Q4 25 | 7.9% | 34.4% | ||
| Q3 25 | 8.2% | 31.7% | ||
| Q2 25 | 7.8% | 36.4% | ||
| Q1 25 | 8.1% | 21.7% | ||
| Q4 24 | 8.6% | 32.6% | ||
| Q3 24 | 8.0% | 8.5% | ||
| Q2 24 | 7.6% | 26.3% |
每股收益（稀释后）GDLLY
| Q1 26 | $4.10 | — | ||
| Q4 25 | — | $7.39 | ||
| Q3 25 | — | $6.21 | ||
| Q2 25 | — | $6.29 | ||
| Q1 25 | — | $3.06 | ||
| Q4 24 | — | $4.88 | ||
| Q3 24 | — | $1.07 | ||
| Q2 24 | — | $3.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.7B | $7.3B |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $26.1B | $26.5B |
| 总资产 | $59.0B | $112.5B |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资GDLLY
| Q1 26 | $3.7B | — | ||
| Q4 25 | $2.3B | $7.3B | ||
| Q3 25 | $2.5B | $9.9B | ||
| Q2 25 | $1.5B | $3.5B | ||
| Q1 25 | $1.2B | $3.2B | ||
| Q4 24 | $1.7B | $3.4B | ||
| Q3 24 | $2.1B | $3.5B | ||
| Q2 24 | $1.4B | $3.4B |
总债务GDLLY
| Q1 26 | $6.3B | — | ||
| Q4 25 | $8.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.8B | $29.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益GDLLY
| Q1 26 | $26.1B | — | ||
| Q4 25 | $25.6B | $26.5B | ||
| Q3 25 | $24.4B | $23.8B | ||
| Q2 25 | $23.6B | $18.3B | ||
| Q1 25 | $22.2B | $15.8B | ||
| Q4 24 | $22.1B | $14.2B | ||
| Q3 24 | $23.0B | $14.2B | ||
| Q2 24 | $22.0B | $13.6B |
总资产GDLLY
| Q1 26 | $59.0B | — | ||
| Q4 25 | $57.2B | $112.5B | ||
| Q3 25 | $57.6B | $114.9B | ||
| Q2 25 | $56.9B | $100.9B | ||
| Q1 25 | $56.6B | $89.4B | ||
| Q4 24 | $55.9B | $78.7B | ||
| Q3 24 | $57.3B | $75.6B | ||
| Q2 24 | $55.4B | $71.9B |
负债/权益比GDLLY
| Q1 26 | 0.24× | — | ||
| Q4 25 | 0.32× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.40× | 2.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.2B |
| 自由现金流经营现金流 - 资本支出 | $2.0B | — |
| 自由现金流率自由现金流/营收 | 14.5% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | — | 0.49× |
| 过去12个月自由现金流最近4个季度 | $6.2B | — |
8季度趋势，按日历期对齐
经营现金流GDLLY
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $2.1B | $8.8B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $-148.0M | $1.7B | ||
| Q4 24 | $2.2B | $2.5B | ||
| Q3 24 | $1.4B | $3.7B | ||
| Q2 24 | $814.0M | $1.5B |
自由现金流GDLLY
| Q1 26 | $2.0B | — | ||
| Q4 25 | $952.0M | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $-290.0M | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $613.0M | — |
自由现金流率GDLLY
| Q1 26 | 14.5% | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 14.7% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | -2.4% | — | ||
| Q4 24 | 13.5% | — | ||
| Q3 24 | 10.4% | — | ||
| Q2 24 | 5.1% | — |
资本支出强度GDLLY
| Q1 26 | 1.5% | — | ||
| Q4 25 | 4.2% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — |
现金转化率GDLLY
| Q1 26 | — | — | ||
| Q4 25 | 1.37× | 0.49× | ||
| Q3 25 | 1.99× | 1.58× | ||
| Q2 25 | 1.58× | 0.55× | ||
| Q1 25 | -0.15× | 0.60× | ||
| Q4 24 | 1.88× | 0.56× | ||
| Q3 24 | 1.52× | 3.83× | ||
| Q2 24 | 0.90× | 0.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GD
暂无分部数据
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
